
may pm et
summari compani develop novel antibodi therapeut target varieti rare sever
diseas state includ autoimmun disord inflamm cancer
price-to-earnings oper ep
risk assess reflect view
depend expand number approv use
soliri support premium valuat mani new
explor indic earli middl stage
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
look sale rise
soliri sale growth moder
growth respect
see strensiq sale kanuma
sale slower uptak price
concern februari
recommend kanuma juli
reach fund agreement england
strensiq becam effect novemb
deal franc becam effect
top-lin phase switch data
show patient
effect safe switch treatment
soliri everi two week treatment
show non-inferior soliri primari
endpoint four secondari endpoint
safeti profil consist
soliri total data favor
soliri plan file
regulatori submiss europ
japan yet
uncertain mani patient
stabl soliri make switch
see ep
think share trade
ep estim slightli peer near
fair valu balanc faster growth
rate risk heavi depend
soliri octob fda approv
soliri treatment gener
myasthenia gravi spite phase trial
fail meet primari endpoint
met secondari endpoint think safeti
profil soliri high level unmet need
achiev secondari endpoint
led approv think indic
like increas soliri sale around
encourag top-lin data
phase trial treat
debilit potenti life-threaten
rare blood disord also monitor
potenti continu manag turmoil
four senior manag depart compani
risk recommend target price
includ slower-than-anticip sale soliri
pipelin failur includ
target price base
peer ep estim
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop novel antibodi therapeut target
varieti sever disord includ autoimmun cardiovascular diseas inflamm cancer
market product soliri eculizumab first therapi approv treatment patient
paroxysm nocturn hemoglobinuria pnh soliri design inhibit specif aspect
complement compon immun system therebi treat inflamm associ chronic
hematolog neurolog disord transplant reject autoimmun disord
soliri human monoclon antibodi complement inhibitor block cleavag compon
complement cascad prevent final stage complement activ soliri
develop treatment pnh rare blood disord caus anemia fatigu dark-color
urin hemoglobinuria pnh portion patient red blood cell miss complement inhibitor
caus abnorm fragil destroy normal complement activ
estim pnh patient european union japan march
said expect pnh popul come rest world
prior soliri approv phn patient gener requir regular blood transfus
soliri also approv second indic rare kidney diseas atyp hemolyt urem syndrom
ahu often lead end-stag kidney diseas failur carri high mortal rate
septemb fda approv soliri use european union regul approv drug
novemb although ahu seen modest launch trajectori state
expect opportun rival pnh
pipelin alexion current pipelin led research effort explor addit use activ
ingredi soliri eculizumab octob report phase ii studi conduct
mayo clinic includ patient rare neurolog disord neuromyel optica nmo result
patient find attack-fre month treatment expect
advanc indic receiv orphan drug design europ
registr studi also anticip initi registr studi neurolog condit
myasthenia gravi show promis phase ii result late exploratori use soliri
includ among kidney transplant patient risk delay graft function dgf receiv fda
orphan drug statu januari prevent acut antibody-medi reject
februari acquir privat held enobia pharma million front paid cash
debt million futur mileston enobia lead candid asfotas alfa report posit
phase ii result orphan disord hypophosphatasia march grant breakthrough
therapi design fda may plan file fda approv around
januari acquir privat held million cash potenti
mileston payment six futur product taligen pre-clin pipelin includ potenti novel
program ophthalm diseas age-rel macular degener antibodi
protein regul complement inflammatori pathway
ultra-rar diseas program pipelin includ cpmp replac therapi
pre-clin studi treatment patient molybdenum cofactor defici genet metabol
disord fatal newborn program grant fda breakthrough therapi design
octob novel complement inhibitor phase studi iv
sub-cutan formul phase studi anti-inflammatori antibodi
phase studi report posit initi phase i/ii dose studi anti-canc molecul
samalizumab monoclon antibodi target pathway initi focu chronic
lymphocyt leukemia cll pre-clin studi cancer vaccin target dc sign receptor path
januari enter collabor privat held discov
develop messeng rna-bas medicin rare diseas made million up-front
payment purchas ten product option made million equiti purchas
june acquir synageva biopharma geva nr billion consist
cash share geva share geva focus rare diseas geva
kanuma treatment lysosom acid lipas defici orphan drug statu us eu
global oper
senior vice presid
independ chairman
board
senior vice-president law
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci
howev anticip modest
overal sale growth mainli due forecast
mid-teen sale declin
biotech sale rose low singl
digit follow growth
follow robust growth period
compound annual growth
rate think sale growth
somewhat limit heighten focu high
drug price encourag view
strong period report
late-stag clinic result
accommod fda approv
fda approv new drug --
sinc record approv
howev fda approv
new drug significantli robust
new drug approv think mani
newly-approv drug signific
commerci prospect repres major
advanc therapi diseas
sclerosi cancer fda
approv first time gene-therapi drug
involv remov patient immun cell
genet alter alter
cell re-introduc patient
help fight cancer
expect wider adopt biomark research
genetic-target clinic studi help
late fda introduc breakthrough
therapi design intend speed
develop promis program expect
favor merger acquisit climat
larg pharmaceut firm move off-set
lost revenu expir drug patent
larg biotech bolster drug pipelin amid
larger scale acquisit
fda author govern biosimilar
drug approv set exclus
advanc modest rate next
sever year march fda
approv novarti filgrastim biosimilar
sandoz began sell biosimilar
name zarxio septemb april
fda approv inflectra manufactur
celltrion co-market inflectra
biosimilar johnson johnson
remicad began ship inflectra
risk novemb discount
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug howev note
prescript benefit manag health
insur exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 biotech index rose vs
rise year date
april biotech index
fell vs declin
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
set ep estim although see sale
growth moder still see above-industri growth rate look soliri
grow growth
respect sale newer drug strensiq kanuma achiev sale
respect see slower uptak price concern
 recommend limit usag strensiq recommend kanuma
inc rais
target peer ep estim file
delay investig soliri sale
practic admit inappropri busi conduct led
pull-in sale million
said found instanc soliri sale place
custom patient order fulfil actual need kept
result outlook think file remov overhang
share think tighten control complianc /jeffrey loo
et capit iq keep hold opinion share
ceo david hallal cfo vika
sinah resign effect immedi former astrazeneca ceo david
brennan becom interim ceo search successor david
former cfo honeywel becom cfo surpris
resign note come amid investig sale practic
relat main drug soliri caus firm delay file
lower target ep estim
peer faster growth rate remain cautiou uncertainti
analyst research note compani news
keep target price
slightli peer ep estim
ep vs ahead estim sale rose
soliri sale strensiq kanuma share
significantli follow posit top-lin phase switch
clinic trial data show patient paroxysm
nocturn hemoglobinuria pnh effect safe switch treatment
soliri everi two week treatment everi eight week studi
show non-inferior soliri primari endpoint four
secondari endpoint safeti profil consist soliri
believ total data favor soliri
plan file regulatori submiss europ
japan howev uncertain mani patient
stabl soliri make switch /jeffrey loo cfa
inc lower target
slightli above-p ep estim
set ep ep vs ahead
estim sale rose soliri sale strensiq
kanuma much lower base guid sale
soliri sale ep expect data
phase trial treat paroxysm nocturn
hemoglobinuria pnh debilit potenti life-threaten rare
blood disord /jeffrey loo cfa
keep target
peer forward ep ep vs
ahead view rais ep estim
sale rose soliri sale
strensiq kanuma rose much smaller base see steadi
growth soliri sale fda emea approv addit
indic also look improv strensiq sale fund deal
england becom effect novemb new agreement franc becom
effect /jeffrey loo cfa
inc rais target
peer forward ep estim
ep vs ahead estim rais ep
estim soliri sale rose
volum rose strensiq sale rose
encourag alxn fund deal nation
base manag access agreement provid strensiq
patient pediatr onset hypophosphatasia kanuma sale
view /jeffrey loo cfa
keep target price
peer ep estim faster growth
ep vs estim sale rose
aid chang revenu recognit certain non-u market
soliri sale rose million streniq sale million
compar million year ago better anticip driven
new patient initi howev expect pricing-per-pati lower due
lower price negoti uk regul increas access
strensiq on-going /jeffrey loo cfa
inc lower
target peer ep estim
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
